Literature DB >> 24102654

Benign lymphangioendothelioma: a clinical, histopathologic and immunohistochemical analysis of four cases.

Lei Wang1, Liuqing Chen, Xichuan Yang, Tianwen Gao, Gang Wang.   

Abstract

BACKGROUND: Benign lymphangioendothelioma represents a rare lymphatic vascular proliferation characterized by proliferation of irregular and thin-walled vessels dissecting amongst dermal collagen. Immunohistochemical analysis has been lacking in most previously reported cases.
METHODS: Herein, we report the clinical and histopathologic characteristics of four cases of benign lymphangioendothelioma. Immunohistochemical study was completed for all lesions.
RESULTS: All lesions presented as large, red to brown patches or plaques. Three lesions were located on the thigh and one lesion was located on the neck. Histopathologically, all lesions showed proliferation of anastomotic or retiform thin-walled vessels with a single layer of endothelial cells that dissect the dermis. D2-40 and Prox1 immunostains were positive and Wilms tumor 1 (WT-1) immunostain was negative in all cases.
CONCLUSION: Benign lymphangioendothelioma represents a lymphatic vascular proliferation. A lack of expression of WT-1 suggests it represents a lymphatic vascular malformation.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  D2-40; Prox 1; Wilms tumor 1; acquired progressive lymphangioma; benign lymphangioendothelioma; vascular malformation

Mesh:

Substances:

Year:  2013        PMID: 24102654     DOI: 10.1111/cup.12216

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  1 in total

1.  Post-mastectomy benign lymphangioendothelioma of the skin following chronic lymphedema for breast carcinoma: a teaching case mimicking low-grade angiosarcoma and masquerading as Stewart-Treves syndrome.

Authors:  Sohsuke Yamada; Yoko Yamada; Miwa Kobayashi; Ryosuke Hino; Aya Nawata; Hirotsugu Noguchi; Motonobu Nakamura; Toshiyuki Nakayama
Journal:  Diagn Pathol       Date:  2014-10-29       Impact factor: 2.644

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.